ADMA Biologics (NASDAQ:ADMA) Reaches New 52-Week High - What's Next?

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Friday . The company traded as high as $22.30 and last traded at $21.67, with a volume of 779556 shares changing hands. The stock had previously closed at $19.72.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. HC Wainwright lifted their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday. Cantor Fitzgerald restated an "overweight" rating and issued a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. Finally, Raymond James upped their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research report on Friday. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $21.25.

ADMA Biologics Stock Up 14.7 %

The company has a market cap of $5.27 billion, a price-to-earnings ratio of 166.36 and a beta of 0.64. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. The business has a 50-day simple moving average of $18.01 and a 200-day simple moving average of $13.73.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, beating analysts' consensus estimates of $0.08 by $0.05. The business had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The company's revenue was up 78.4% on a year-over-year basis. During the same period last year, the business earned ($0.02) EPS. On average, equities analysts anticipate that ADMA Biologics, Inc. will post 0.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other ADMA Biologics news, Director Young Kwon sold 60,000 shares of the business's stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the sale, the director now directly owns 241,441 shares in the company, valued at approximately $4,408,712.66. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the sale, the director now owns 241,441 shares in the company, valued at approximately $4,408,712.66. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Adam S. Grossman sold 236,889 shares of the business's stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the transaction, the chief executive officer now directly owns 2,059,726 shares of the company's stock, valued at $36,436,552.94. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 466,900 shares of company stock worth $8,224,121 in the last quarter. Company insiders own 3.70% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. D. E. Shaw & Co. Inc. increased its stake in ADMA Biologics by 26.8% in the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company's stock valued at $76,298,000 after purchasing an additional 1,442,799 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of ADMA Biologics by 2.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company's stock worth $69,454,000 after acquiring an additional 92,281 shares during the period. Driehaus Capital Management LLC boosted its position in shares of ADMA Biologics by 17.3% in the second quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company's stock worth $33,860,000 after acquiring an additional 447,743 shares during the last quarter. Renaissance Technologies LLC grew its holdings in ADMA Biologics by 28.7% in the second quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company's stock valued at $28,868,000 after purchasing an additional 575,100 shares during the period. Finally, Federated Hermes Inc. increased its position in ADMA Biologics by 15.5% during the second quarter. Federated Hermes Inc. now owns 1,969,811 shares of the biotechnology company's stock worth $22,022,000 after purchasing an additional 263,677 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.